Introduction

Arthrosamid injections are becoming a popular option for managing knee osteoarthritis, especially for those who haven’t found sufficient relief with traditional treatments. These injections involve a specially designed gel that is introduced into the knee joint to cushion and protect damaged cartilage. This helps reduce pain and improve movement. Interest in Arthrosamid is growing across the UK, making it important to understand how you can access this treatment through both NHS and private routes. This guide will help you navigate the options and make informed choices about your care.

What Are Arthrosamid Injections and How Do They Work?

Arthrosamid is a cross-linked polymer gel injected directly into the knee joint. It acts like a synthetic cartilage, cushioning the joint to ease pain and improve mobility, especially in moderate to severe knee osteoarthritis. Importantly, research shows that “injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported” (Cole et al., 2022). Further laboratory studies support its safety, with findings confirming that “2.5 iPAAG demonstrates no apparent in vitro neurotoxic or cytotoxic effects in human iCell® Glutaneurons” (Walmod et al., 2025). This treatment is usually suited for patients who haven’t experienced enough benefit from physiotherapy, medications, or other injections. Recent evidence suggests that “iPAAG offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited” (Aykaç et al., 2025), meaning that Arthrosamid can be a helpful addition to individualised osteoarthritis care. Always seek advice from a qualified healthcare professional to see if this treatment is right for you.

Accessing Arthrosamid Injections: NHS Versus Private Healthcare

Access to Arthrosamid injections varies depending on whether you use the NHS or go private. On the NHS, availability is limited and often depends on where you live and local NHS policies. Your GP will usually need to refer you to an orthopaedic or musculoskeletal specialist for an assessment. Waiting times can be long, and not all NHS regions offer this treatment routinely. If you choose private healthcare, you can generally access Arthrosamid injections more quickly, often without long waiting lists. Searching online with terms like “Arthrosamid injection near me” or “availability of Arthrosamid injection” can help you find local private clinics. Supporting this, research has found “statistically significant data was identified in two studies at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection” (Cole et al., 2022). Private providers typically offer thorough consultations and personalised care plans. Bear in mind the cost involved, and weigh this against waiting times and availability on the NHS.

Finding the Right Clinic and Ensuring High-Quality Care

Choosing a trusted clinic is essential when considering Arthrosamid injections. Look for clinics with well-qualified staff, strong credentials, and positive patient feedback. Your GP can be a helpful guide in recommending reputable specialists or centres. It’s especially beneficial to seek out clinics that focus on cartilage and musculoskeletal health, as they have expert knowledge in this area. A key expert is Professor Paul Lee, a Cartilage Specialist and Regional Surgical Ambassador recognised for his clinical experience and advisory role with the Royal College of Surgeons of Edinburgh. Clinics such as MSK Doctors pride themselves on professional, patient-centred care designed to support a good recovery. Selecting a centre with this level of expertise can make a real difference to your treatment journey.

What to Expect: Consultation, Treatment, and Aftercare

Your journey to receiving Arthrosamid injections usually begins with an initial consultation, either through an NHS referral or a private appointment. During this visit, your specialist will discuss your symptoms and review scans or X-rays to check if you’re a suitable candidate. They will explain the procedure, potential benefits, and any risks. The injection itself is straightforward — a minimally invasive procedure done in a clean, outpatient setting. As research confirms, “PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years” (Cole et al., 2022). After the injection, you’ll receive advice on how to care for your knee and what activities to avoid. Follow-up appointments are important to monitor your progress. Studies also show that “iPAAG showed the highest patient acceptable symptom state rates (72%, 54%, and 42% at 3, 6, and 12 months)” (Aykaç et al., 2025), underscoring patient satisfaction. Remember to ask your healthcare provider any questions about recovery or ongoing care to stay well informed.

Helpful Resources and Next Steps

If you want to learn more about Arthrosamid and knee osteoarthritis, official NHS websites and professional groups like the British Orthopaedic Association and the British Knee Society are excellent starting points. Patient support organisations and respected health information platforms can offer useful insights and shared experiences. Ultimately, your treatment choices should be made together with your healthcare team, tailored to suit your individual needs. While access to Arthrosamid injections may differ based on where you live and whether you’re on the NHS or private care, taking informed steps and seeking expert advice will help you find the best path to managing your knee health. By understanding your options and working closely with knowledgeable clinicians, you can confidently explore Arthrosamid injections as a valuable part of your knee osteoarthritis treatment plan—helping you move more comfortably and enjoy an improved quality of life.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(14), e44655. https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430